Fig. 4

Exosomal miR-335 promoted osteogenic differentiation of BM-MSCs by targeting LATS1. LATS1 mRNA (a) and protein (b, c) levels in BM-MSCs in the groups of control, induction, mDC-Exo, and mDC-Exo-NC, and mDC-Exo-miR-335I on the 7th day of culture. **P < 0.01, vs. Control; ^#P < 0.05, vs. mDC-Exo-NC. d Predicted binding sites for miR-335 in the 3′-UTR of LATS1 (Targetscan). e The interaction between miR-335 and LAST1 3′-UTR was analyzed by luciferase activity assay. **P < 0.01, vs. mimic NC. LAST1 mRNA (f) and protein (g) levels in BM-MSCs transfected with miR-335 mimics, mimic NC, miR-335 inhibitors, or inhibitor NC. *P < 0.05, **P < 0.01, vs. mimic NC; ^#P < 0.05, vs. inhibitor NC. h, i The protein levels of LATS1, p-LAST1, YAP, p-YAP, TAZ, and p-TAZ, j ALP activities expressed in optical density (OD) values at 520 nm, k–m Runx2 mRNA and protein levels in BM-MSCs transfected with LAST1 overexpression vector/empty vector and treated with mDC-Exo or PBS. *P < 0.05, **P < 0.01, vs. vector + PBS; ^#P < 0.05, ^##P < 0.01, vs. vector + mDC-Exo